Saurabh Gurnurkar, Executive Director, Uquifa states that CDMOs have begun to incorporate the latest innovations in all aspects of their operations. Whether this implementation happens in science, in manufacturing equipment, or communication technologies, CDMOs are pushing the boundaries
See below a link to an important communication regarding the status of our operations and the meassures UQUIFA is taking to address the pandemic crisis caused by the coronavirus COVID-19 outbreak.
As per the recent research report published by Fact.MR, the global Acute Pyelonephritis Treatment Market is on course to achieve a highly eye-catching growth. The research report predicts the market is expected to expand at a healthy CAGR of X.XX% over the course of the given period of forecast ranging from 2018 to 2028. The valuation of the global Acute Pyelonephritis Treatment Market was around US$X.XX%. Given the rate of development, the new valuation of the market will be around US$XX.XX by the end of the forecast period in 2028. The Fact.MR research provides detailed information about the key segments, driving and restraining factors, geographical outlook, and the present situation of the vendor landscape of the global Acute Pyelonephritis Treatment Market.
Union Quimico Farmaceutica on FDA Import Alert List
UQUIFA-Union Farmaceutica S.A. on Health Canada Inspection List
The Global Active Pharmaceutical Ingredient (API) Market has seen a steady growth in volume and value mirroring the growth drivers for the overall pharmaceutical industry. However clearly this year has seen a significant impact of supply disruptions from the conventional supplier base i.e China and India impacting either API availability or economics. At Uquifa, we make API and we have seen the input prices for quite a few products in our portfolio go up. There are several factors which have contributed for the raw materials prices to go dearer, key reason being environmental concerns in China which have forced the government to rationalize manufacture in many zones. The lack of supply or higher prices of inputs have meant the escalation in API prices with a spillover to the finished drug in some cases too. At Uquifa, we are typically buying 60% of our raw material inputs from China and clearly the volatility in supply and pricing impacts us meaningfully.
Vivimed`s Uquifa expects Euro 200 mn revenues in 4 yrs
See below a link to an important communication regarding the status of our operations and the meassures UQUIFA is taking to address the pandemic crisis caused by the coronavirus COVID-19 outbreak.
We have renewed the Certification of Responsible Company. We have demonstrated the fulfillment of its requirements, within the Responsible Care Program and its principles of Environmental Management , Safety, Hygiene, Sustainable Development and Corporate Social Responsiblility
Miguel Angel Maceda, General Manager of UQUIFA-Mexico has signed the Uquifa Compliance Policy, which applies to all UQUIFA workcenters in Spain and Mexico, confirming the commitment of UQUIFA to accomplist the legal and ethics principles of the companies signing the Corporate Social Responsability.